71.53
+0.54(+0.76%)
Currency In USD
Address
950 Tower Lane
Foster City, CA 94404
United States of America
Phone
650 667 4085
Website
Sector
Healthcare
Industry
Biotechnology
Employees
334
First IPO Date
July 18, 2019
| Name | Title | Pay | Year Born |
| Mr. Christopher Peetz | Chief Executive Officer & Director | 1.54M | 1979 |
| Ms. Lara Longpre MBA, MSC | Chief Development Officer | 678,200 | 1970 |
| Dr. Joanne M. J. Quan M.D. | Chief Medical Officer | 827,424 | 1964 |
| Mr. Eric H. Bjerkholt M.B.A., M.S. | Chief Financial Officer | 860,887 | 1960 |
| Mr. Peter Radovich M.B.A., Ph.D. | Chief Operating Officer & President | 990,050 | 1978 |
| Mr. Paul K. Ross | Chief Compliance Officer | 0 | N/A |
| Mr. Andrew McKibben | Senior Vice President, Strategic Finance & Investor Relations | 0 | N/A |
| Mr. Douglas T. Sheehy J.D. | Chief Legal Officer | 0 | 1967 |
| Dr. Jean-Luc Girardet Ph.D. | Chief Technical Officer | 0 | N/A |
| Ms. Erin Campany | Chief People Officer | 0 | 1968 |
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.